α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Autor: R. Paniagua, Melissa Reeves, F. Arce Vargus, Julia Malato, A. Mirza, Hidetoshi Mori, Rosemary J. Akhurst, M. Adoumie, Mikhail Binnewies, Byron Hann, B. Liang, Michael Rosenblum, O. Li, Minh D. To, Miranda Broz, Dominique S. Meyer, D. Sheppard, Sergio A. Quezada, Allan Balmain, T. Buchmann, Di Wu, Matthew F. Krummel, Eswari Dodagatta-Marri, R. del Rosario

Publikováno v: Journal for immunotherapy of cancer, vol 7, iss 1
Dodagatta-Marri, E; Meyer, DS; Reeves, MQ; Paniagua, R; To, MD; Binnewies, M; et al.(2019). α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.. Journal for immunotherapy of cancer, 7(1), 62. doi: 10.1186/s40425-018-0493-9. UCSF: Retrieved from: http://www.escholarship.org/uc/item/28t115w7
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)

Background Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1601fcdaed83828a09f9e659c007e4fb
https://escholarship.org/uc/item/28t115w7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Additional file 3: of α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Autor: E. Dodagatta-Marri, D. Meyer, M. Reeves, R. Paniagua, M. To, M. Binnewies, M. Broz, H. Mori, D. Wu, M. Adoumie, R. Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. Hann, A. Mirza, S. Quezada, M. Rosenblum, M. Krummel, A. Balmain, R. Akhurst

Figure S1. Growth responses of CCK62 and GEK1428 to immunotherapy. Figure S2. CCK168 responses to α-PD-1 and/or α-TGFβ. Figure S3. α-TGFβ and α-TGFβ/α-PD-1 combination therapy elicit long-term tumor immunity to Kras-driven tumors. Figure S4.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fa321eec4572986f53c2caf933bab5f

Additional file 1: of α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Autor: E. Dodagatta-Marri, D. Meyer, M. Reeves, R. Paniagua, M. To, M. Binnewies, M. Broz, H. Mori, D. Wu, M. Adoumie, R. Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. Hann, A. Mirza, S. Quezada, M. Rosenblum, M. Krummel, A. Balmain, R. Akhurst

Supplementary Methods. (DOCX 9 kb)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcfa50cc4b3c768e7fe73dbae2c6dd24